期刊
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
卷 10, 期 4, 页码 272-282出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/187152010791162270
关键词
Anticancer; platinum(II) complexes; binuclear platinum(II) complexes; multinuclear platinum(II) complexes
资金
- Research Project Foundation of Shijiazhuang Bureau of Science Technology [07120053A]
- Research Project Foundation of Baoding Bureau of Science Technology [07F05]
- Key Basic Research Special Foundation of Science Technology Ministry of Hebei Province [08966415D]
- Research Project Foundation of Department of Hebei Education [2008311]
Cisplatin has become one of the most commonly used compounds for the treatment of a wide spectrum of human malignancies. Unfortunately, cisplatin has several major drawbacks. Driven by the impressive impact of cisplatin on cancer chemotherapy, great efforts have been made to develop new derivatives with improved pharmacological properties. Among the over 30 platinum agents which have entered clinical trials after the onset of clinical studies with cisplatin in the early 1970s, only carboplatin and oxaliplatin have received worldwide approval so far, nedaplatin, lobaplatin and heptaplatin have gained regionally limited approval. It has become quite evident that mere analogues of cisplatin or carboplatin will not probably offer any substantial clinical advantages over the existing drugs. Therefore, people turned to synthesize non-classical platinum anticancer drugs which were capable of forming a different range of DNA adducts which could display a different spectrum of anticancer activity compared to cisplatin. This review will summarize the structural types and structure-activity rules of non-classical bi- and multi-nuclear platinum anticancer drugs, and discuss their future potential as anticancer agents.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据